Literature DB >> 8384366

Antitumor agents. 125. New 4 beta-benzoylamino derivatives of 4'-O-demethyl-4-desoxypodophyllotoxin and 4 beta-benzoyl derivatives of 4'-O-demethylpodophyllotoxin as potent inhibitors of human DNA topoisomerase II.

X M Zhou1, Z Q Wang, H X Chen, Y C Cheng, K H Lee.   

Abstract

A series of 4 beta-benzoylamino (5-17) derivatives of 4'-O-dimethyl-4- desoxypodophyllotoxin and 4 beta-benzoyl (18-20) derivatives of 4'-O-demethyl podophyllotoxin have been synthesized and evaluated for their inhibitory activity against the human DNA topoisomerase II as well as for their activity in causing cellular protein-linked DNA breakage. Compounds 5-13 and 15-17 are more potent than etoposide in causing DNA breakage, while compounds 9, 10, 13, 14, 16, and 20 are more active than etoposide in their inhibition of the human DNA topoisomerase II. The order for the enzyme inhibitory activity of the derivatives of 4'-O-demethyl-4-desoxypodophyllotoxin is 4 beta-arylamino > 4 beta-benzylamino > 4 beta-benzoylamino.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384366     DOI: 10.1023/a:1018978525533

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  Antitumor agents, 107. New cytotoxic 4-alkylamino analogues of 4'-demethyl-epipodophyllotoxin as inhibitors of human DNA topoisomerase II.

Authors:  K H Lee; Y Imakura; M Haruna; S A Beers; L S Thurston; H J Dai; C H Chen; S Y Liu; Y C Cheng
Journal:  J Nat Prod       Date:  1989 May-Jun       Impact factor: 4.050

Review 2.  Mechanism of action of antitumor drug etoposide: a review.

Authors:  J M van Maanen; J Retèl; J de Vries; H M Pinedo
Journal:  J Natl Cancer Inst       Date:  1988-12-07       Impact factor: 13.506

3.  Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide.

Authors:  J C Shah; J R Chen; D Chow
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

4.  Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.

Authors:  G L Chen; L Yang; T C Rowe; B D Halligan; K M Tewey; L F Liu
Journal:  J Biol Chem       Date:  1984-11-10       Impact factor: 5.157

5.  Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial.

Authors:  J D Hainsworth; S D Williams; L H Einhorn; R Birch; F A Greco
Journal:  J Clin Oncol       Date:  1985-05       Impact factor: 44.544

6.  Antitumor agents. 113. New 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II.

Authors:  Z Q Wang; Y H Kuo; D Schnur; J P Bowen; S Y Liu; F S Han; J Y Chang; Y C Cheng; K H Lee
Journal:  J Med Chem       Date:  1990-09       Impact factor: 7.446

7.  Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.

Authors:  W Ross; T Rowe; B Glisson; J Yalowich; L Liu
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

Review 8.  DNA topoisomerases in cancer therapy.

Authors:  R B Lock; W E Ross
Journal:  Anticancer Drug Des       Date:  1987-10

9.  Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage.

Authors:  T Rowe; G Kupfer; W Ross
Journal:  Biochem Pharmacol       Date:  1985-07-15       Impact factor: 5.858

10.  Antitumor agents. 124. New 4 beta-substituted aniline derivatives of 6,7-O,O-demethylene-4'-O-demethylpodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II.

Authors:  Z Q Wang; H Hu; H X Chen; Y C Cheng; K H Lee
Journal:  J Med Chem       Date:  1992-03-06       Impact factor: 7.446

View more
  5 in total

1.  Design, synthesis and cytotoxic activity of novel sulfonylurea derivatives of podophyllotoxin.

Authors:  Zhi-Jun Zhang; Jing Tian; Li-Ting Wang; Mei-Juan Wang; Xiang Nan; Liu Yang; Ying-Qian Liu; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Bioorg Med Chem       Date:  2013-11-28       Impact factor: 3.641

2.  A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II.

Authors:  Gaik-Lean Chee; Jack C Yalowich; Andrew Bodner; Xing Wu; Brian B Hasinoff
Journal:  Bioorg Med Chem       Date:  2009-11-27       Impact factor: 3.641

3.  Antitumor agents. 126. Novel 4 beta-substituted anilino derivatives of 3',4'-O,O-didemethylpodophyllotoxin as potent inhibitors of human DNA topoisomerase II.

Authors:  Z Q Wang; Y C Shen; H X Chen; J Y Chang; X Guo; Y C Cheng; K H Lee
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

Review 4.  Recent progress on C-4-modified podophyllotoxin analogs as potent antitumor agents.

Authors:  Ying-Qian Liu; Jing Tian; Keduo Qian; Xiao-Bo Zhao; Susan L Morris-Natschke; Liu Yang; Xiang Nan; Xuan Tian; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2014-05-14       Impact factor: 12.944

5.  Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.

Authors:  Malgorzata N Drwal; Jessica Marinello; Stefano G Manzo; Laurence P G Wakelin; Giovanni Capranico; Renate Griffith
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.